Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17139566 | METHOD FOR MAKING REDUCTION SENSITIVE NANO MICELLES | December 2020 | August 2022 | Allow | 20 | 0 | 0 | No | No |
| 17256853 | COMPOSITION OF ALGINIC OLIGOSACCHARIC DIACIDS | December 2020 | June 2022 | Allow | 17 | 2 | 0 | Yes | No |
| 17256738 | USE OF MANNURONIC DIACID COMPOSITION IN TREATMENT OF VASCULAR DEMENTIA | December 2020 | May 2022 | Allow | 17 | 2 | 0 | Yes | No |
| 17125474 | COMPOUNDS | December 2020 | November 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 17253128 | Nutritional composition for improving intestinal barrier integrity, preparation of the composition and method of treatment | December 2020 | January 2023 | Allow | 25 | 1 | 0 | No | No |
| 17251429 | NOVEL DOSAGE FORMS OF LACTULOSE | December 2020 | October 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17115186 | COMPOSITIONS AND METHODS FOR TREATING EYE DISEASES | December 2020 | March 2021 | Allow | 3 | 1 | 0 | Yes | No |
| 17115242 | HIGH ELASTICITY HYALURONAN COMPOSITIONS AND METHODS OF USE THEREOF | December 2020 | October 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 17058533 | TARGETED NANOPREPARATION OF MANNOSE, AND PREPARATION THEREFOR AND APPLICATION THEREOF | November 2020 | March 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17056635 | GREEN WOOD ADHESIVE | November 2020 | March 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17098884 | POLYMER GELS, METHOD OF PREPARATION AND USES THEREOF | November 2020 | June 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17096178 | RAPID-ACTING INSULIN FORMULATION COMPRISING A SUBSTITUTED ANIONIC COMPOUND | November 2020 | January 2022 | Allow | 14 | 0 | 0 | Yes | No |
| 17089344 | COMPOSITIONS AND METHODS FOR TREATMENT OF A CORONAVIRUS DISEASE (COVID-19) INFECTION | November 2020 | May 2023 | Abandon | 30 | 4 | 0 | Yes | No |
| 17078239 | NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND NUCLEOTIDES AND USES THEREOF FOR TREATING AND/OR PREVENTING ENTERIC VIRAL INFECTION | October 2020 | February 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 17070810 | HEALTH SUPPLEMENT | October 2020 | January 2022 | Allow | 15 | 3 | 0 | Yes | No |
| 17046164 | PHYTOCHEMICAL-ANTIBIOTIC COMBINATION FOR THE TREATMENT OF A BACTERIAL INFECTION | October 2020 | March 2022 | Allow | 18 | 0 | 0 | Yes | No |
| 17062269 | MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS | October 2020 | February 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17044946 | Prebiotic Compositions And Methods Of Production Thereof | October 2020 | March 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17060343 | OPHTHALMIC COMPOSITIONS WITH IMPROVED DESSICATION PROTECTION AND RETENTION | October 2020 | May 2022 | Allow | 19 | 2 | 0 | No | No |
| 17026910 | COMPOSITION FOR TREATING JOINT DISEASE AND KIT CONTAINING SAME | September 2020 | October 2021 | Allow | 13 | 0 | 0 | Yes | No |
| 17024368 | ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND | September 2020 | February 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17021066 | NANO-CRYSTALLINE CELLULOSE | September 2020 | September 2021 | Allow | 12 | 0 | 0 | Yes | No |
| 17007533 | HYALURONIC ACID COMPOSITION FOR PENILE INJECTIONS | August 2020 | July 2021 | Abandon | 11 | 1 | 0 | No | No |
| 17001118 | SYNTHETIC COMPOSITION FOR MICROBIOTA MODULATION | August 2020 | February 2023 | Allow | 30 | 1 | 0 | No | No |
| 16997727 | POLYMORPHIC FORMS OF DEOXYCYTIDINE, COMPOSITIONS COMPRISING THE SAME AND USES | August 2020 | January 2023 | Allow | 29 | 2 | 0 | No | No |
| 16320047 | MEDICAMENT | August 2020 | December 2021 | Abandon | 35 | 2 | 0 | Yes | No |
| 16966530 | PARASITICIDAL COMPOSITIONS COMPRISING EPRINOMECTIN AND PRAZIQUANTEL, METHODS AND USES THEREOF | July 2020 | November 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16763969 | COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDER COMPRISING AUCUBIN | July 2020 | August 2021 | Allow | 15 | 1 | 0 | No | No |
| 16939390 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION | July 2020 | April 2022 | Abandon | 21 | 1 | 0 | No | No |
| 16964882 | TREATMENT OF HEARING LOSS | July 2020 | October 2022 | Allow | 27 | 0 | 1 | Yes | No |
| 16964542 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF POSTOPERATIVE PAIN | July 2020 | December 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16927629 | HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | July 2020 | May 2024 | Abandon | 46 | 4 | 0 | No | No |
| 16961085 | METHODS AND COMPOSITIONS FOR TREATING PRE-ECLAMPSIA | July 2020 | August 2023 | Allow | 37 | 0 | 0 | Yes | No |
| 16923154 | GLYCOCONJUGATION PROCESS | July 2020 | May 2021 | Allow | 10 | 0 | 0 | Yes | No |
| 16959141 | METHOD TO PREPARE A FILLER WITH A HYALURONIC ACID BASE USING SPECIFIC CROSSLINKING AGENTS | June 2020 | August 2022 | Allow | 26 | 1 | 0 | No | No |
| 16910775 | NUTRITIONAL COMPOSITIONS WITH MFGM AND CERTAIN HUMAN MILK OLIGOSACCHARIDES AND USES THEREOF | June 2020 | August 2023 | Allow | 37 | 2 | 0 | Yes | No |
| 16946455 | SENSITIVE OLIGONUCLEOTIDE SYNTHESIS USING SULFUR-BASED FUNCTIONS AS PROTECTING GROUPS AND LINKERS | June 2020 | September 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16907913 | THERAPEUTIC AGENT FOR NERVOUS SYSTEM DISEASE | June 2020 | February 2022 | Allow | 20 | 2 | 0 | Yes | No |
| 16907132 | INJECTABLE GEL PRODUCT | June 2020 | March 2022 | Allow | 21 | 1 | 0 | No | No |
| 16955495 | COMPOSITIONS COMPRISING AT LEAST ONE N-ACETYLATED AND AT LEAST ONE FUCOSYLATED OLIGOSACCHARIDE FOR USE IN THE PROMOTION OF DIGESTIVE CAPACITY IN INFANTS AND YOUNG CHILDREN | June 2020 | August 2022 | Allow | 26 | 2 | 0 | Yes | No |
| 16955326 | COMPOSITION COMPRISING SULPHATED GALACTOSE, AND IMPLEMENTATIONS THEREOF | June 2020 | February 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 16903511 | Insecticidal Compositions And Methods To Kill Insects | June 2020 | May 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 16954401 | ORAL ADMINISTRATION FORMULATION OF BLUEBERRY EXTRACT AS A COADJUVANT FOR PRESERVING THE HEALTH OF HUMAN PRECORNEAL FILM | June 2020 | November 2023 | Allow | 41 | 4 | 0 | Yes | No |
| 16898123 | PHARMACEUTICAL USE OF ARGININYL FRUCTOSY GLUCOSE | June 2020 | August 2021 | Allow | 14 | 1 | 0 | No | No |
| 16770530 | IMPROVED ENRICHMENT METHODS FOR PREPARING TANNIC ACID COMPOSITIONS | June 2020 | June 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16769851 | OPHTHALMIC DRUG PREPARATION AND USES THEREOF | June 2020 | June 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16887214 | AMORPHOUS ERTUGLIFLOZIN AND PROCESS FOR ITS PREPARATION | May 2020 | February 2022 | Abandon | 21 | 1 | 0 | No | No |
| 16768333 | MIXTURE OF HMOS FOR TREATING WHEAT SENSITIVITY | May 2020 | May 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 16767928 | USE OF AGAR-DERIVED OLIGOSACCHARIDES FOR INHIBITING GROWTH OF STAPHYLOCOCCUS | May 2020 | April 2022 | Allow | 22 | 1 | 0 | No | No |
| 16884628 | TREATMENT OF ALPHAVIRUS-INDUCED INFLAMMATION | May 2020 | December 2022 | Allow | 31 | 2 | 0 | Yes | No |
| 16883380 | Method for treatment of cellular senescence | May 2020 | September 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16766404 | QUERCETIN-BASED COMPOSITION FOR TREATING RHINOSINUSITIS | May 2020 | January 2022 | Allow | 20 | 1 | 0 | No | No |
| 16765349 | COMPOSITION FOR PREVENTING OR IMPROVING INTRINSIC AGING COMPRISING PAEONIFLORIN OR ALBIFLORIN | May 2020 | June 2022 | Allow | 25 | 2 | 0 | No | No |
| 16865697 | METHOD AND COMPOSITION FOR IMPROVED HYDRATION IN ANIMALS | May 2020 | November 2022 | Abandon | 30 | 2 | 0 | No | No |
| 16761164 | ONE OR MORE HMOS FOR REDUCING OR PREVENTING FATIGUE AND/OR IMPROVING FOCUS OR CONCENTRATION | May 2020 | July 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16862662 | THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS | April 2020 | October 2020 | Allow | 5 | 1 | 0 | No | No |
| 16759818 | AMPK ACTIVATING AGENT | April 2020 | July 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16859027 | METHODS AND COMPOSITIONS FOR EXTENDING LIFESPAN | April 2020 | June 2021 | Abandon | 13 | 1 | 0 | No | No |
| 16758995 | INHIBITING REDUCTION OF LEAN BODY MASS AND INHIBITING ACCUMULATION OF LIVER FAT BY ADMINISTERING ALLULOSE | April 2020 | October 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16759167 | ADJUVANTED VACCINES | April 2020 | May 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16857279 | INJECTABLE SHEAR-THINNING HYDROGELS AND USES THEREOF | April 2020 | June 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16858479 | TEMPERATURE-RESPONSIVE DEGRADABLE HYDROGELS | April 2020 | August 2021 | Allow | 16 | 0 | 0 | No | No |
| 16758668 | SOLUBILIZATION ENHANCER FOR PYRROLOQUINOLINE QUINONE, COMPOSITION COMPRISING SAME AND METHOD FOR ENHANCING SOLUBILIZATION | April 2020 | August 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16757864 | FUNCTIONALIZED HYALURONIC ACID OR A DERIVATIVE THEREOF IN THE TREATMENT OF INFLAMMATORY STATES | April 2020 | August 2021 | Allow | 16 | 0 | 0 | No | No |
| 16756199 | CEREBRAL HYPOFUNCTION INHIBITOR OR CEREBRAL HYPOFUNCTION PROPHYLACTIC AGENT CONTAINING CAROTENOID COMPOSITION | April 2020 | November 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16848640 | RAPID-ACTING INSULIN FORMULATION COMPRISING A SUBSTITUTED ANIONIC COMPOUND | April 2020 | August 2020 | Allow | 4 | 1 | 0 | No | No |
| 16754756 | Application of Low-Molecular-Weight Hyaluronic Acid (LMW-HA) Fragments | April 2020 | September 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16652001 | HIGH MOLECULAR WEIGHT CHITOSAN, PROCESS FOR OBTAINING AND USES THEREOF | March 2020 | November 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16651243 | COMPOSITIONS AND METHODS FOR TREATING SEPTIC CARDIOMYOPATHY | March 2020 | December 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16821613 | FOOD FOR IMPROVING INTESTINAL ENVIRONMENT | March 2020 | January 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 16820767 | CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS | March 2020 | November 2020 | Allow | 8 | 1 | 0 | No | No |
| 16812767 | METHOD FOR PRODUCING HYDROGELS COUPLING HIGH ELASTIC MODULUS AND ABSORBANCE | March 2020 | May 2021 | Allow | 14 | 1 | 0 | No | No |
| 16645068 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | March 2020 | August 2022 | Allow | 29 | 2 | 0 | Yes | No |
| 16643969 | USE OF VERBASCOSIDE IN PREPARATION OF DRUG FOR PREVENTING OR TREATING GLOMERULAR PODOCYTE INJURED RENAL DISEASE | March 2020 | May 2022 | Allow | 27 | 3 | 0 | Yes | No |
| 16642976 | METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS | February 2020 | January 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16643215 | PRODUCTION METHOD FOR ACIDIC XYLOOLIGOSACCHARIDE, AND ACIDIC XYLOOLIGOSACCHARIDE | February 2020 | November 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16641638 | OIL AND FAT COMPOSITION CONTAINING UNSATURATED FATTY ACID | February 2020 | February 2024 | Abandon | 48 | 4 | 0 | No | No |
| 16796632 | SYNERGISTIC ANTIOXIDANT COMPOSITIONS | February 2020 | October 2020 | Allow | 8 | 0 | 0 | Yes | No |
| 16790330 | RUTIN COMPOSITIONS | February 2020 | December 2020 | Allow | 10 | 2 | 0 | Yes | No |
| 16633390 | USE OF SOPHOROLIPIDS AS FEED ADDITIVE | January 2020 | August 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16632742 | NEUROPROTECTIVE ISOFLAVONE COMPOSITIONS AND METHODS | January 2020 | April 2022 | Abandon | 26 | 2 | 0 | No | No |
| 16632408 | A METHOD FOR BIOFILM DISPERSAL | January 2020 | March 2023 | Allow | 38 | 2 | 0 | No | No |
| 16630309 | SAPONIN COMPOUND TARGETING PD-1 AND APPLICATION THEREOF | January 2020 | February 2022 | Allow | 25 | 1 | 0 | No | No |
| 16730079 | COMPOSITION CONTAINING OROXYLIN A AND METHOD OF EXTRACTION THEREOF | December 2019 | October 2021 | Abandon | 21 | 2 | 0 | No | No |
| 16729755 | BRANCHED POLYETHYLENE GLYCOL EPOXY DERIVATIVE CROSSLINKED SODIUM HYALURONATE GEL, PREPARATION AND APPLICATION THEREOF | December 2019 | November 2021 | Allow | 22 | 1 | 0 | No | No |
| 16730139 | METHODS FOR PREVENTING OR MITIGATING ACUTE ALLERGIC RESPONSES USING HUMAN MILK OLIGOSACCHARIDES | December 2019 | May 2021 | Allow | 17 | 2 | 0 | Yes | No |
| 16721443 | OPHTHALMIC COMPOSITIONS WITH IMPROVED DESSICATION PROTECTION AND RETENTION | December 2019 | August 2020 | Allow | 8 | 2 | 0 | Yes | No |
| 16624858 | COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | December 2019 | June 2022 | Allow | 30 | 0 | 0 | Yes | No |
| 16620921 | IMMUNOGENIC COMPOSITION | December 2019 | February 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16619445 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | December 2019 | August 2024 | Abandon | 56 | 2 | 0 | No | No |
| 16687339 | RAPID-ACTING INSULIN FORMULATION COMPRISING A SUBSTITUTED ANIONIC COMPOUND | November 2019 | February 2020 | Allow | 3 | 0 | 0 | Yes | No |
| 16614401 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MUTANT KCNJ5 | November 2019 | June 2022 | Allow | 31 | 1 | 0 | No | No |
| 16614249 | METHODS AND COMPOSITIONS FOR IMPROVING SLEEP | November 2019 | July 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16611827 | BLADDER INSTILLATION COMPOSITION WITH INCREASED STORAGE STABILITY AND CONTAINING CHONDROITIN SULFATE (4.5 MG/ML), HYALURONIC ACID (16 MG/ML) AND PHOSPHATE BUFFER (PH 6.1 TO 7.9), FOR THE TREATMENT OF CYSTITIS | November 2019 | April 2022 | Allow | 29 | 0 | 0 | Yes | No |
| 16674786 | DRUG COMPOUND AND PURIFICATION METHODS THEREOF | November 2019 | July 2020 | Allow | 9 | 0 | 0 | Yes | No |
| 16609283 | METHOD FOR PREPARING AN AQUEOUS HYALURONIC ACID GEL | October 2019 | August 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16666586 | COMPOSITION FOR ENHANCING EXERCISE ABILITY OR ANTI-FATIGUE COMPRISING NOVEL GINSENOSIDE | October 2019 | February 2021 | Allow | 15 | 1 | 0 | Yes | No |
| 16609168 | STABLE NICOTINAMIDE RIBOSIDE COMPOSITION AND PREPARATION METHOD THEREOF | October 2019 | April 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16607531 | TREATING AND PREVENTING KIDNEY DAMAGE | October 2019 | July 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16660111 | WATER SOLUBLE O-GLYCOSYL FLAVONOID COMPOSITIONS AND METHODS FOR PREPARING SAME | October 2019 | May 2021 | Allow | 18 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MILLER, DALE R.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MILLER, DALE R works in Art Unit 1623 and has examined 322 patent applications in our dataset. With an allowance rate of 69.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 27 months.
Examiner MILLER, DALE R's allowance rate of 69.6% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MILLER, DALE R receive 1.88 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MILLER, DALE R is 27 months. This places the examiner in the 69% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +17.3% benefit to allowance rate for applications examined by MILLER, DALE R. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 28.9% of applications are subsequently allowed. This success rate is in the 56% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 45.5% of cases where such amendments are filed. This entry rate is in the 70% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 63.6% of appeals filed. This is in the 43% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 87.8% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.